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ABSTRACT 
Inflammation is the first response of the immune system to harmful stimuli such as infection or irritation, consists of a cascade of biochemical 
events that propagates and matures the inflammatory response. Numbers of anti-inflammatory drugs are available for treatment of acute and 
chronic inflammation. Many anti-inflammatory drugs cause adverse side effects. The quinoline class of compounds are important for searching 
the safe and effective anti-inflammatory drugs. These drugs are classified based on the number of substituents present on the quinoline ring or 
compounds containing a quinoline ring fused to other heterocyclic compounds. Quinolines have the ability to target several ca uses of 
inflammation includes transient receptor potential vanilloid 1 receptor. The TRPV1 receptor, first cloned and characterized in 1997, is a non-
selective cation channel expressed in primary sensory neurons, and is a key pain sensor and integrator. This review provides the discovery of 
various quinoline derivatives as transient receptor potential vanilloid 1 (TRPV1) antagonists. Overall, the quinoline moiety will be used as a 
new template for designing and identifying the novel anti-inflammatory drugs in future.  
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INTRODUCTION 
Inflammation, the first response of the immune system to 
harmful stimuli such as infection or irritation, consists of a 
cascade of biochemical events that propagates and matures 
the inflammatory response.1 It is a protective attempt by the 
organism to remove the injurious stimuli and initiate the 
healing process. However, if uncontrolled, inflammation can 
lead to a diverse array of acute, chronic and systemic 
inflammatory disorders.2-4 
Usually, during acute inflammatory responses, 
cellular and molecular events and interactions efficiently 
minimize impending injury or infection. This mitigation 
process contributes to restoration of tissue homeostasis and 
resolution of the acute inflammation. However, uncontrolled 
acute inflammation may become chronic, contributing to a 
variety of chronic inflammatory diseases.5 
At tissue level, inflammation is characterized by 
redness, swelling, heat, pain, and loss of tissue function, 
which result from local immune, vascular and inflammatory 
cell responses to infection or injury.6 Important 
microcirculatory events that occur during the inflammatory 
process include vascular permeability changes, leukocyte 
recruitment and accumulation, and inflammatory mediator 
release.7 Various pathogenic factors, such as infection, tissue 
injury, or cardiac infarction, can induce inflammation by 
causing tissue damage. The etiologies of inflammation can be 
infectious or non-infectious. In response to tissue injury, the 
body initiates a chemical signaling cascade that stimulates 
responses aimed at healing affected tissues. These signals 
activate leukocyte chemotaxis from the general circulation 
to sites of damage. These activated leukocytes produce 
cytokines that induce inflammatory responses.8 
Quinolines act as anti-inflammatory agents 
Quinoline is heterocyclic aromatic organic 
compound containing nitrogen and was first isolated in 1834 
by Runge from coal tar and he named it as Leukol. Later in 
1842, Gerhardt isolated it by heating the alkaloid cinchonine 
with alkali and named as quinoline.9 These heterocycles 
have been of considerable interest because a large number 
of natural products and drugs contain this heterocyclic 
unit.10  
Quinolines have attracted particular attention 
owing to their diverse array of pharmacological properties 
including the ability to target several causes of inflammation 
including transient receptor potential vanilloid 1 (TRPV1) 
antagonists.1 Several reviews have appeared on the 
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anticancer or antitumor11,12, antimalarial13 and antimicrobial 
activities14 of quinolines. This review will focus on targets of 
inflammation that is transient receptor potential vanilloid 1 
followed by the quinoline-based modulators which acts as 
TRPV1 antagonists. 
Transient Receptor Potential (TRP) Family 
 The transient receptor potential (TRP) superfamily 
is one of the largest families of ion channels and comprises 
28 members.15,16 Based on amino acid sequence homology, 
the mammalian members of TRP channel family have been 
classified into six subfamilies: TRPC (Canonical), TRPV 
(Vanilloid), TRPM (Melastatin), TRPP (Polycystin), TRPML 
(Mucolipin) and TRPA (Ankyrin). The TRPV subfamily 
consists of a group of four channels, TRPV1, TRPV2, TRPV3 
and TRPV4 that are critically involved in nociception and 
thermosensing, and two additional channels TRPV5 and 
TRPV6 that appear to be constitutively active and have been 
proposed to play a role in vitamin D dependant calcium 
uptake in the kidney and intestine respectively.17,18  
Targeting TRPV1: Vanilloid receptor antagonists 
 The TRPV1 receptors, found in the peripheral and 
central nervous systems, are involved in the transmission 
and modulation of pain, as well as the integration of diverse 
painful stimuli. This receptor channel is activated by protons 
(pH 5, chemical stimuli), heat (>42oC, physical stimuli), 
endogeneous substances (such as endocannabinoid 
anandamide, lipoxygenase and arachidonic acid metabolites) 
and also by some natural ligands (such as capsaicin, other 
vanilloids and resiniferatoxin). This results in Ca2+ influx 
into the cells through the channel pore, causing cell 
membrane depolarisation and excitation of primary sensory 
neurons. It then transmits noxious nerve impulses to the 
spinal cord and finally delivers the perception of pain.1,19 
Upon continued stimulation from any external stimuli the 
activity of neurotransmitters is depleted causing selective 
damage of the nerves and, thereby, results in desensitisation 
to further stimuli. As a result, TRPV1 receptors lose 
sensitivity to painful stimuli. Various TRPV1 agonists were 
used to treat pains (e.g. capsaicin, resiniferatoxin, etc.). 
However, several adverse side effects like burning sensation, 
irritation and neurotoxicity that were associated with this 
approach shifted the focus toward the discovery of TRPV1 
antagonists. These antagonists block the pain signalling 
pathway with potentially fewer side effects.20-22 
 TRPV1 has been shown to be important in both 
nociception (the perception of pain) and the inflammatory 
responses.23,24 It is considered to be a highly validated target 
for pain, and both agonists and antagonists of TRPV1 are 
being evaluated as potential analgesics in clinical trials. 
Simply, its antagonists block the function of TRPV1 and 
relieve pain behaviours caused by inflammation, 
osteoarthritis and cancer in rodent models. Its agonists, such 
as capsaicin, cause desensitization of TRPV1 channels that 
relieves pain behaviours in preclinical species.25,26 The initial 
drug discovery research targeting TRPV1 was mainly 
focused on agonists; a dermal capsaicin patch is already on 
market for long-term treatment for neuropathic pain.27,28 
However, most of the agonists have initial burning effects 
making their therapies complicated, and therefore, more 
focused consideration has been given to the antagonists for 
developing novel analgesic drugs.29 
The first reported TRPV1 antagonist, capsazepine, 
was discovered by chemical modification from capsaicin. 
The amide bond of capsaicin was replaced by a thiourea 
group, and the amide nitrogen being a part of a bicyclic ring 
to form an orthogonal orientation with respect to the 
thiourea bond. Unfortunately, it was not a candidate for 
clinical use due to its low metabolic stability, poor 
pharmacokinetic properties and nonselectivity to other 
channels.28 Using this scaffold as a template, small molecule 
TRPV1 antagonists with various chemotypes have been 
discovered over the years.30-33 The classical TRPV1 ligands 
share three functional regions that act as pharmacophores 
(Figure 1)23: i) an aromatic group (A-region), which mimics 
the vanilloid moiety of capsaicin; ii) a linker (B-region) such 
as ester, amide, urea and thiourea; and iii) an aliphatic group 
(C-region), which corresponds to a lipophilic octanyl moiety 
of capsaicin.  
 
Figure 1. Pharmacophores of the representative TRPV1 
ligands. For capsaicin, resiniferatoxin and capsazepine, three 
important pharmacophore regions are marked. 
Nonclassical TRPV1 ligands have a carbonyl group, 
which is either present as a part of heterocyclic ring or is 
unrecognizable.23 The preclinical studies and clinical trials 
showed that the side effects such as hyperthermia and 
impaired noxious heat sensation (burn risk) are the main 
obstacles for developing TRPV1 antagonists.27 There has 
been a need to distinguish the excitatory effects and the 
analgesic effects of  TRPV1, and it has been actively studied 
whether these side effects are on-target, that is, unavoidable, 
or can be mitigated by chemical modifications.34 Based on 
these efforts, second generation of TRPV1 antagonists that 
do not induce hyperthermia are under development27, and 
several compound series show promising results for 
overcoming these side effects.  
This review focuses on the development of 
quinoline as TRPV1 antagonists with an emphasis on recent 
research in this field. 
Quinoline as TRPV1 Antagonist 
 Many monosubstituted quinolines have been 
reported as TRPV1 antagonists. Compounds 1 and 2 were 
prepared by acylation of quinoline with 4-
(trifluoromethylthio)phenyl isocyanate.29 The activities of 
compounds were measured by a Ca2+ influx assay using 
human TRPV1 receptor.35 The screening of compounds with 
single nitrogen containing bicyclic cores for their 
antagonistic activity at human TRPV1 revealed that the 
quinoline derivative 2 (IC50 = 420 nM) exhibited superior 
potency to the regioisomeric quinoline 1 (IC50 = 1500 nM).29
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N-Aryl cinnamide 3 (AMG9810), identified 
independently through the screening studies at Amgen, was 
also found to be a highly selective TRPV1 receptor 
antagonist when profiled against more than 80 different 
drug targets. Compound 3 blocks the capsaicin-induced 
uptake of Ca2+ in TRPV1 expressing CHO cells with an IC50 
value of 17 nM. Compound 3 was found to block TRPV1 
activation by capsaicin as well as other agonists such as 
acids and heat.15 SAR studies using 3 as a lead compound led 
to a series of N-aryl cinnamide, the most potent of which 
were the quinolines 4a and 4b with IC50 values of 1.9 and 
0.42 nM, respectively. These compounds exhibit good oral 
bioavailability in rats with Foral = 39% and 17%, respectively, 
compared to negligible oral bioavailability (Foral = 3%) 
observed for the lead 3.36 
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a X = O         b X = CH2 
SAR studies around HTS hit 5 led to the identification of the N-quinolin-7-yl-6-phenylnicotinamide 6 which was identified as a 
potent TRPV1 antagonist with activity in an in vivo model of inflammatory pain.37  
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This compound possessed excellent potency at 
human and rat TRPV1 receptors and a favourable in vitro 
DMPK profile. However, the low intrinsic clearance observed 
in liver microsomes [CLi 3.1 (human), 2.2 (rat), 3.9 (guinea 
pig) mL/min/g tissue] did not translate into acceptable in 
vivo stability in the rat (CLb 33 mL/min/kg, T½ 0.36 h at 1 
mg/kg iv). Furthermore, compound 6 showed only modest 
activity in the guinea pig model of Freunds Complete 
Adjuvant (FCA)-induced inflammatory pain and was less 
efficacious than expected based on its high level of in vitro 
potency. Further optimisation of this lead series targeting, in 
particular, an improved in vivo profile. This work has 
resulted in the identification of a compound which showed 
excellent levels of activity in the guinea pig FCA model on 
oral dosing. Initial efforts focused on modification of the 
terminal phenyl ring of 6. Substituted analogues 7 and 8 
were prepared from methyl 6-chloronicotinate and the 
appropriate boronic acid using Suzuki–Miyaura coupling 
conditions38 followed by hydrolysis and standard EDCI-
mediated amide coupling. Alternatively, compounds 9 – 12 
were prepared directly from chloro-nicotinamide.37 
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As illustrated in Table 137, the introduction of a 
fluoro-substituent into the 2- or 3-positions, 7 and 8, was 
well tolerated giving compounds with potency similar to 
that of the unsubstituted parent 6. The 4-fluoro substituted 
compound 9 showed ⁓3-fold lower potency at TRPV1 with 
pKb 8.2 but following determination of in vitro ADME 
properties it was found that this compound possessed the 
best overall in vitro profile in this series with an acceptable 
P450 inhibition profile (IC50 >10 µM at five major human 
isoforms), and low intrinsic clearance in human and rat liver 
microsomes [CLi 1.7 (human), 1.1 (rat) mL/min/g tissue]. 
However, in guinea pig microsomes, 9 proved to be a high-
clearance compound (CLi 42 mL/min/g). Replacement of 4-F 
with 4-Cl, 4-CF3 or 4-CN 10-12 was detrimental to potency 
and complete replacement of the terminal phenyl ring with 
smaller groups such as cyano 13 or chloro 14 also resulted 
in reduced levels of TRPV1 antagonist activity. 
Table 1: Antagonist activity of nicotinamide derivatives 6 
and 7-14 at human TRPV1 expressed in a 1321N1 cell line40 
against capsaicin in FLIPR (Fluorescence Imaging Plate 
Reader) assay 
Compound R1 hTRPV1a pKb 
6 Ph 8.7 
7 2-FPh 8.7 
8 3-FPh 8.6 
9 4-FPh 8.2 
10 4-ClPh 7.8 
11 4-CF3Ph 7.3 
12 4-CNPh ˂6.6 
13 4-CN <6.7 
  14 4-Cl <6.7 
a Standard error of mean (SEM) for all pKb values ≤ 0.1 
To investigate the effect of altering the 
conformation around the biaryl amide linker, the 2- and 4-
methylnicotinamide analogues 15, 16 and 17 were 
prepared.  
Interestingly, it was found that the presence of a 
methyl in the 2-position was beneficial to TRPV1 antagonist 
potency, compounds 15 and 16, whereas the 4-
methylnicotinamide 17 was much less active (Table 2)37.  
N NH
O
N
R
1
R
2
R
3
 
15-17 
Table 2: Antagonist activity of methylnicotinamide 
derivatives at human TRPV1 expressed in a 1321N1 cell 
line40 against capsaicin in FLIPR (Fluorescence Imaging Plate 
Reader) assay 
Compound R1 R2 R3 hTRPV1a pKb 
15 Me H H 9.0 
16 Me H F 8.5 
17 H Me H 6.7 
a SEM ≤ 0.1 for 15 and 16, SEM = 0.3 for 17 
The reduced potency seen with 17 may be due to 
the 4-methyl group causing a conformational change 
resulting in the pyridyl nitrogen in 17 occupying an 
alternative and less favourable position in the active site 
when compared to the 2-methyl analogue 15 and 
unsubstituted analogue 6. The 2-methylnicotinamide 16 was 
tested in a guinea pig model of FCA induced inflammatory 
pain39 and showed 42% reversal of hyperalgesia at a dose of 
5 mg/kg ip. Although this represented a significant 
improvement over the activity of 6 in the same in vivo model 
(32% reversal at 30 mg/kg sc). 
An efficient synthesis of 2-amino-oxazolo[4,5-
c]quinoline TRPV1 antagonists is described via a thiourea 
formation/carbodiimide cyclization sequence. Synthetic 
route optimization eliminates intermediate isolations and 
facilitates the rapid preparation of a series of novel 
pentacyclic TRPV1 antagonists 18-24. From this series, 
compound 22 was identified as a potent and selective 
TRPV1 antagonists with hTRPV1 IC50 = 5 nM and > 100-fold 
selectivity versus other TRP channels.41 
        
NH
NO
N
OH
                        
NH
NO
N
OH
F
                      
NH
NO
N
OH
F
                      
NH
NO
N
OH
Cl
 
    18                    19                20            21 
 
                     
NH
NO
N
OH
F3C
                     
NH
NO
N
OH
F3C
                    
NH
NO
N
OH
CF3
  
     22          23               24 
Ambatkar et al                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):782-788 
ISSN: 2250-1177                                                                                  [786]                                                                                 CODEN (USA): JDDTAO 
Many monosubstituted quinolines have been 
reported as TRPV1 antagonists.1 One such report identified 
quinoline derivatives 25 and 26 possessing oral 
bioavailability in rats (F = 39% and 17%, respectively) as 
promising agents in the capsaicin (CAP) mediated functional 
assay (IC50 = 1.9 and 0.42 nM, respectively) and the pH-
mediated assay (IC50 = 1.3 and 1.0 nM, respectively). The 
maximum plasma concentrations for 25 and 26 were Cmax = 
540 ng/ml and 320 ng/ml at 5 mg/kg p.o., respectively.36
N NH
O
N
N
O
CF3            
N NH
O
N
N
CF3 
25       26 
SAR on a series of conformationally constrained 
analogues of the cis conformer of compounds 25 and 26 
identified 7-oxo and 8-oxoquinoline derivatives 27 and 28 
as TRPV1 antagonists. Compound 27 was orally bioavailable 
(F = 31% in rats) and showed potent antagonism against rat 
TRPV1 [rTRPV1 (CAP) IC50 = 7.4 nM and rTRPV1 (acid) IC50 
= 8.0 nM] and human TRPV1 [hTRPV1 (CAP) IC50 = 3.7 nM 
and hTRPV1 (acid) IC50 = 4.2 nM] in CAP and acid-mediated 
assays.36 It also blocked TRPV1-mediated physiological 
response in the CAP-induced hypothermia model in rats. 
However, it was inefficacious at preventing thermal 
hyperalgesia generated by complete Freund’s adjuvant in 
rats.42 Therefore, to improve the potency and 
pharmacokinetic (PK) properties of 27, the 8-oxoquinoline 
derivative 28 [rTRPV1 (CAP) IC50 = 15 nM] was designed 
with an encouraging microsomal stability.43 Compound 28 
was cleared at the rate of 44 and 135 ml/min/mg in rat and 
human, respectively, compared with 111 and 250 
ml/min/mg for compound 27. 
N O
NN
CF3
      
N
O
NN
CF3
 
27               28 
A quinoline carboxamide derivative 29 with N-
methyl substitution showed moderate activities against 
hTRPV1 (pKb = 6.5) with capsaicin as the agonist.44 
Optimisation of 29 led to the development of compound 30, 
with a carboxamide at the 7-position and no substitution on 
the quinoline nitrogen. Compound 30 exhibited good levels 
of in vitro metabolic stability (CLi < 5 ml/min/g liver) in 
human, rat, guinea pig and dog liver microsomes and also 
P450 inhibition with IC50 values >18 µM at five major human 
isoforms (1A2, 2C9, 2C19, 2D6 and 3A4). It also showed 
excellent potency against hTRPV1 [pIC50 (acid) = 8.1] and 
rTRPV1 receptors [pIC50 (acid) = 7.6].44 Overall, quinolines 
with carboxamide substitution and 8-oxo-substituted 
quinolines showed promising TRPV1 antagonism.1 
Trisubstituted tetrahydroquinoline urea 31 has 
been reported as a TRPV1 antagonist in human TRPV1 
calcium influx assay and an inhibitor of CYP3A4 enzyme 
(hTRPV1 IC50 = 7 nM and 47% CYP3A4 inhibition at 10 
µM).45 Another compound, 32 with 5,5 diphenyl 
pentadienamide moiety at the 4- position was also reported 
as a TRPV1 antagonist.46 The (R)-enantiomer of 32 (hTRPV1 
IC50 = 0.14 and rTRPV1 0.35 nM) was more potent than the 
(S)-32 in the capsaicin-based assay and showed good PK 
profile in rats, dogs and monkeys. The (R)-32 was effective 
at preventing mechanical allodynia in rats in a dose 
dependent manner and reversed thermal hyperalgesia in a 
model of neuropathic pain induced by sciatic nerve injury.46
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CONCLUSION 
From all above the information, it is cleared that the 
heterocyclic moiety quinolines have importance in searching 
the safe and effective next generation anti-inflammatory 
drugs. This is explained by the discovery of various 
quinoline derivatives as TRPV1 receptor antagonists and the 
activities of these derivatives depend on the nature and 
position of substituents present on the quinoline ring or 
compounds containing a quinoline ring fused to other 
heterocyclic compounds. Overall, the quinoline moiety can 
be used as a new template for designing and identifying the 
novel anti-inflammatory drugs to treat the diseases 
associated with inflammation in future.  
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